ATE365735T1 - Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel - Google Patents

Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel

Info

Publication number
ATE365735T1
ATE365735T1 AT04734875T AT04734875T ATE365735T1 AT E365735 T1 ATE365735 T1 AT E365735T1 AT 04734875 T AT04734875 T AT 04734875T AT 04734875 T AT04734875 T AT 04734875T AT E365735 T1 ATE365735 T1 AT E365735T1
Authority
AT
Austria
Prior art keywords
böthiophene
cycloalkylsulfanyl
therapeutic agents
substituted benzo
diseases
Prior art date
Application number
AT04734875T
Other languages
English (en)
Inventor
Rocco Dean Gogliotti
Helen Tsenwhei Lee
Karen Elaine Sexton
Melean Visnick
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE365735T1 publication Critical patent/ATE365735T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04734875T 2003-06-05 2004-05-26 Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel ATE365735T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47597103P 2003-06-05 2003-06-05

Publications (1)

Publication Number Publication Date
ATE365735T1 true ATE365735T1 (de) 2007-07-15

Family

ID=33511739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734875T ATE365735T1 (de) 2003-06-05 2004-05-26 Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel

Country Status (9)

Country Link
US (1) US20040248954A1 (de)
EP (1) EP1636212B1 (de)
JP (1) JP2006526610A (de)
AT (1) ATE365735T1 (de)
BR (1) BRPI0410940A (de)
CA (1) CA2527341A1 (de)
DE (1) DE602004007268D1 (de)
MX (1) MXPA05013210A (de)
WO (1) WO2004108714A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
EP2091565A2 (de) * 2006-11-29 2009-08-26 Genentech, Inc. Verfahren zur diagnose und behandlung von gliomen
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
AP2011005956A0 (en) * 2009-04-20 2011-10-31 Gilead Calistoga Llc Methods of treatment for solid tumors.
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
NZ629684A (en) 2012-03-05 2016-10-28 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
EP3694511A1 (de) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationsbehandlung von pankreasarzinom
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954748A (en) * 1968-07-29 1976-05-04 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France 3-Alkoxy-thianapthene-2-carboxamides
IE58555B1 (en) * 1984-12-10 1993-10-06 Warner Almbert Company Novel benzothiophenes and benzofurans having antiallergy activity
US4703053A (en) * 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
US4800211A (en) * 1986-08-18 1989-01-24 Merck & Co., Inc. 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as cyclooxygenase and lipoxygenase inhibitors
US4767776A (en) * 1987-02-20 1988-08-30 Warner-Lambert Company N-1H-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents
US4764525A (en) * 1987-02-25 1988-08-16 Warner-Lambert Company N-1H-tetrazol-5-ylbenzamides having use as antiallergy and antiinflammatory agents
US4931459A (en) * 1987-07-14 1990-06-05 Warner-Lambert Company Method for treating acute respirator distress syndrome
IE64995B1 (en) * 1987-07-14 1995-09-20 Warner Lambert Co Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
US5468898A (en) * 1990-09-10 1995-11-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity
US5208253A (en) * 1992-02-24 1993-05-04 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo(b) thiophene-2-carboxamides as inhibitors of cell adhesion
JPH09500130A (ja) * 1993-07-15 1997-01-07 ワーナー−ランバート・コンパニー 炎症性腸疾患の治療において用いる薬剤としてのベンゾチオフェンおよびベンゾフランおよび炎症をアッセイする方法
US5426113A (en) * 1994-04-08 1995-06-20 Warner-Lambert Company Method of preventing ulcer formation caused by nonsteroidal antiinflammatory drugs employing tetrazol-benzothiophene carboxamide compounds
HRP950288A2 (en) * 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
DE69601765T2 (de) * 1995-09-07 1999-07-08 Oreal Extrakt von Iridaceen und Zusammensetzungen, die ihn enthalten
DE19911165B4 (de) * 1999-03-12 2008-03-13 Bayer Cropscience Ag Entlaubungsmittel
AR022889A1 (es) * 1999-03-12 2002-09-04 Bayer Cropscience Ag Agente desfoliante
CN1891693A (zh) * 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物

Also Published As

Publication number Publication date
MXPA05013210A (es) 2006-03-09
BRPI0410940A (pt) 2006-08-29
EP1636212B1 (de) 2007-06-27
EP1636212A1 (de) 2006-03-22
WO2004108714A1 (en) 2004-12-16
US20040248954A1 (en) 2004-12-09
DE602004007268D1 (de) 2007-08-09
CA2527341A1 (en) 2004-12-16
JP2006526610A (ja) 2006-11-24

Similar Documents

Publication Publication Date Title
ATE364605T1 (de) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
MXPA05013061A (es) Benzotiofenos sustituidos con cicloalquilos y heterocicloalquilos como agentes terapeuticos.
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
MA28010A1 (fr) Derives de piperazine et leur utilisation comme agents therapeutiques
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
SE0401971D0 (sv) Piperidne derivatives
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DE60045508D1 (de) Dalda-analoge und ihre verwendung
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
DE60208541D1 (de) Antibakterielle mittel
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties